Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to third SARS-CoV-2 vaccination in rituximab-treated patients without prior humoral response
2021-002348-57Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tozinameran, elasomeran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Humoral immune response after third SARS-CoV-2 vaccination. Started May 2021; status: completed.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002348-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002348-57.